Ensuring Drug Security Forum

The success of Russia’s goal to ensure its sustainable national drug sovereignty not only depends on the effectiveness of regulatory decisions, but also on the level of public confidence in domestic drugs. The strategies for improving the reputation of the Russian pharmaceutical industry should be based on constructive interaction between government, business, and the professional and scientific community in the public’s interests. Russia needs sound communication strategies based on the principles of information openness among all institutions involved in this process, a well-reasoned and consistent dialogue, a solid body of evidence, and the high quality and safety profile of domestic medicines. In terms of the information and awareness agenda, we need to create open platforms for cooperation that representatives of the medical community will be able to use to visit pharmaceutical enterprises and learn first-hand about the results of advanced technologies and developments, drug effectiveness indicators, and the quality assurance system in manufacturing in order to become ambassadors of Russian pharmaceutical products for the patient community. What trust factors influence the image of Russian pharmaceutical products and how should we manage them? Which institutions should represent the interests of the Russian pharmaceutical industry in the face of public opinion and what is the best way to involve them in this process? What effective tools can destroy stereotypes in society’s attitude towards domestic drugs and help increase public confidence in Russian medicines?

Moderator
Aleksandr Petrov, Deputy, member of the State Duma Committee on Health Protection of the Federal Assembly of the Russian Federation

Aleksandr Petrov

Deputy, member of the State Duma Committee on Health Protection of the Federal Assembly of the Russian Federation

Panellists
Victor Dmitriev, General Manager, Association of Russian Pharmaceutical Manufacturers; Chairman of the Public Council under the Federal Service for Surveillance in Healthcare
Vasily Ignatiev, General Director, R-Pharm
Guzeliya Imaeva, Chief Executive Officer, NAFI Research Centre
Oxsana Pozdnyakova, General Director, Nizhpharm
Svetlana Semecheva, Deputy Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation (online)
Denis Chetverikov, President, AKRIKHIN
Evgeniya Shapiro, Director General, PSK Pharma
Vladislav Shestakov, Director, State Institute of Drugs and Good Practices

Victor Dmitriev

General Manager, Association of Russian Pharmaceutical Manufacturers; Chairman of the Public Council under the Federal Service for Surveillance in Healthcare

CEO, Association of Russian Pharmaceuticals Manufacturers, member of the Board, Russian Union of Industrialists and Entrepreneurs, member of the Council, Chamber of Trade and Industry of the Russian Federation
PhD in Medicine, a degree from I.M. Sechenov First Moscow Institute of Medicine.
In 2002, he co-founded the Association of Russian Pharmaceuticals Manufacturers and led it until 2004. From 2004 to 2007, he was Deputy Director of Federal State-Owned Institution Research Center for Testing of Medical Applications under the Russian Service for Supervision of Healthcare. In October 2007, a general meeting of the Association once again elected Victor Dmitriev its CEO.
Founded in 2002, the Association of Russian Pharmaceuticals Manufacturers includes leading Russian pharmaceutical companies with around 75% of Russia’s medicine output, more than 40% of exports, and more than 80% of domestically produced medicines for the Essential Medicines Provision Program. The Association’s mission is to develop the Russian pharmaceutical industry to ensure the necessary supplies of modern, quality, and affordable medicines to the public.

Vasily Ignatiev

General Director, R-Pharm

Born in Moscow, Russia on 27 November 1968.
Ignatiev holds an MD – diploma with honours from the I.M. Sechenov First Moscow State Medical University. Expert in clinical pharmacology. Holds a Candidate of Medical Research Degree. Studied at Columbia University College of Physicians and Surgeons (New York, USA). Holds MBA degrees from Moscow International Higher Business School MIRBIS and London Guildhall University (now part of the London Metropolitan University).
For 7 years Ignatiev worked in the Russian branch of the international pharmaceutical company Bristol-Myers Squibb in the positions of Product Manager, Franchise Manager, Marketing Director.
For 5 years Ignatiev served in the Russian branch of the international pharmaceutical company AstraZeneca in the leading positions of Marketing Director and Sales Director.
In 2008, Ignatiev was appointed Director for Business Development in CJSC R-Pharm, a Russian pharmaceutical company. And now he is the Chief Executive Officer.
In 2018 Ignatiev was elected to become Vice Chair of the Board of the Association of International Pharmaceutical Manufacturers.

Guzeliya Imaeva

Chief Executive Officer, NAFI Research Centre

Education
• Russian State Social University, Faculty of Sociology
• Moscow international higher businesses school MIRBIS. Presidential Program for the Training of Management Specialists. Specialization in marketing
• Advancia-Negocia business school, Paris, France

Expertise
• Member of the Expert Council on Digital Economy in the State Assembly of the Russian Federation
• Member of the Expert Council on Financial Literacy of the Central Bank of the Russian Federation
• Member of the Expert Council of the Deposit Insurance Agency
• Member of ESOMAR
• Member of the Russian Society of Sociologists
• The author of dozens of scientific publications and articles in the field of financial behavior of the population and business. Co-author of the books: 100 Facts about Russians’ financial Behavior, Encyclopedia of Russians’ financial behavior, Financial inclusion in Russia: the demand-side perspective, Children and finance: Safety of Savings and payments, Digital Literacy for the Future Economy, Children and Technology
• The winner of the IX All-Russian Business Women Competition Success, 2013

Oxsana Pozdnyakova

General Director, Nizhpharm

Denis Chetverikov

President, AKRIKHIN

Evgeniya Shapiro

Director General, PSK Pharma

Vladislav Shestakov

Director, State Institute of Drugs and Good Practices

Shestakov, Vladislav (born on November 27, 1969, in Salekhard, USSR) is a Director of State Institute of Drugs and Good Practices, Deputy Director of Russian State GMP-Inspectorate.
Before being appointed as a Director of the Institute served as Chairman of the Pharmacy and Biotechnology branch offices of All Russia Public Organization “Business Russia”.
Honorary chemist, a certified inspector and GMP auditor. Russian State GMP-Inspectorate Deputy Head and Head of the GP Committee of the Pharmacy vocational qualifications Council of the National Pharmaceutical Chamber. Since 1997 has been working in the field of healthcare and pharmacy.
Biography
Born on November 27, 1969 in Salekhard, Yamalo-Nenets Autonomous area, USSR. In 1987 he entered the Tyumen State Medical Institute, in 1989 he continued his studies at the Smolensk State Medical Academy. He graduated from the State University of Management (2005), specialty – “State and municipal management”. In 2008 he graduated from the Academy of Labor and Social Relations, “Business Administration”. In 2016 he got a vocational retraining diploma of the Moscow Institute of Physics and Technology (MIPT), "GMP and drugs quality control - theory and practice of GMP-inspection / audit."
2000 - Deputy Director-General, Irbitsky Chemical and Pharmaceutical Plant.
2001-2001 - Vice-president, Rosmedprom.
2002-2003 - Head of commercial department, Hemofarm, Moscow office.
2004-2005 - Deputy Director-General, Makiz-Pharma.
2005 - General Director, Skopinsky Pharmaceutical Plant.
2007 – GR Director, Union of Professional Pharmaceutical Organizations.
2008 – President, Epidbiomed Group of Companies.
2009 - Business Development Director, Binnopharm.
2011-2012 – Counselor to the Director-General, Usolie-Sibirskiy Khimfarmzavod.
2012-2013 – Deputy Director-General, Nanolek.

On November 27, 2013, Shestakov was appointed as Director of State Institute of Drugs and Good Practices.
Since 2003, he has been a regular lecturer of educational programs for professional development in the field of managing the commercial and government organizations’ activities, as well as specialized programs in pharmaceuticals and pharmaceutical production. He has the certificate of the international inspector of WHO on good manufacturing practice.
Awards
• The title of “Honorary Chemist”
• Certificate of Honor from the Minister of Industry and Trade of the Russian Federation “For achieved progress at work”.

Front row participants
Valentina Kosenko, General Director, Scientific Center for Expertise of Medicinal Products of the Ministry of the Ministry of Health of the Russian Federation
Marina Rykova, Director of Strategic Marketing, GEROPHARM

Valentina Kosenko

General Director, Scientific Center for Expertise of Medicinal Products of the Ministry of the Ministry of Health of the Russian Federation

Marina Rykova

Director of Strategic Marketing, GEROPHARM